Tumor suppression and normal aging in mice with constitutively high p53 activity

Genes and Development

Volumn 20, Issue 1, 2006, Pages 16-21

  Mendrysa, Susan M ^a,b,d   O'Leary, Kathleen A ^a,e   McElwee, Matthew K ^a,f   Michalowski, Jennifer ^a,g   Eisenman, Robert N ^b   Powell, Douglas A ^c   Perry, Mary Ellen ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d PURDUE UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f DUKE UNIVERSITY   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Aging; Apoptosis; Cancer therapy; Mdm2; p53; Tumor suppression

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

AGED; AGING; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG TARGETING; GENE FUNCTION; LIFESPAN; MOUSE; NONHUMAN; PREMATURE AGING; PRIORITY JOURNAL;

AGING; ANIMALS; BONE AND BONES; INTESTINAL NEOPLASMS; LEUKOCYTE COUNT; MICE; MICE, MUTANT STRAINS; PROTO-ONCOGENE PROTEINS C-MDM2; SKIN; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MURINAE;

EID: 29944447632     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1378506     Document Type: Article

References (25)

1. Bond, G.L., Wenwei, H., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
2. Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K., and Lane D.P. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes & Dev. 19: 2122-2137.
3. Chao, C., Hergenhahn, M., Kaeser, M.D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., and Xu, Y. 2003. Cell type- and promoter-specific roles of ser18 phosphorylation in regulating p53. J. Biol. Chem. 278: 41028-41033.
4. Cheshire, J.L. and Baldwin, A.S. 1997. Synergistic activation of NF-κB by tumor necrosis factor α and γ interferon via enhanced degradation and de novo IκB β degradation. Mol. Cell. Biol. 17: 6746-6754.
5. Donehower, L.A. 2002. Does p53 affect organismal aging? J. Cell. Phys. 192: 23-30.
6. Febeyre, G. and Lowe, S.W. 2002. The price of tumor suppression? Nature 415: 26-27.
7. Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., Criado, L.M., Klatt, P., Flores, J.M., Weill, J.-C., Blasco, M.A., and Serrano, M. 2002. 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21: 6225-6235.
8. Gentry, A. and Venkatachalam, S. 2005. Complicating the role of p53 in aging. Aging Cell 4: 157-160.
9. Halberg, R.B., Katzung, D.S., Hoff, P.D., Moser, A.R., Cole, C.E., Lubet, R.A., Donehower, L.A., Jacoby, R.F., and Dove, W.F. 2000. Tumorigenesis in the multiple intestinal neoplasia mouse: Redundancy of negative regulators and specificity of modifiers. Proc. Natl. Acad. Sci. 97: 3461-3466.
10. Honda, R., Tanaka, H., and Yasuda, H. 1997. Oncoprotein MDM2 is a ubiquitin ligase for tumor suppressor p53. FEBS Lett. 420: 25-27.
11. Jones, S.J., Roe, A.E., Donehower, L.A., and Bradley, A. 1995. Rescue of embryonic lethality in MDM2-deficient mice by absence of p53. Nature 378: 206-208.
12. Kirk, R.E. 1982. Experimental design: Procedures for the behavioral sciences, 2nd ed., pp. 106-127. Brooks/Cole, Monterey, CA.
13. Lane, D.P. and Fischer, P.M. 2004. Turning the key on p53. Nature 427: 789-790.
14. Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., and Scrable, H. 2004. Modulation of mammalian life span by the short isoform of p53. Genes & Dev. 18: 306-319.
15. Mendrysa, S.M., McElwee, M.K., Michalowski, J., O'Leary, K.A., Young, K.M., and Perry, M.E. 2003. Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing radiation. Mol. Cell. Biol. 23: 462-473.
16. Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transcription. Cell 69: 1237-1245.
17. Montes de Oca Luna, R., Wagner, D.S., and Lozano, G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
18. Moser, A.R., Pitot, H.C., and Dove, W.F. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324.
19. Potoff, R.F. 1964. On the Johnson-Neyman technique and extensions thereof. Psycometrika 29: 241-256.
20. Roth, J.M., Dobbelstein, M., Freedman, D.A., Shenk, T., and Levine, A.J. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the level of p53 via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554-564.
21. Strate, L.L. and Syngal, S. 2005. Hereditary colorectal cancer syndromes. Cancer Causes Control 16: 201-213.
22. Thut, C.J., Goodrich, J.A., and Tjian, R. 1997. Repression of p53-mediated transcription by MDM2: A dual mechanism. Genes & Dev. 11: 1974-1986.
23. Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. 2002. P53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53.
24. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
25. Yang, Y., Ludwig, R.L., Jensen, J.P., Pierre, S.A., Medaglia, M.V., Davydov, I.V., Safiran, Y.J., Oberoi, P., Kenten, J.H., Phillips, A.C., et al. 2005. Small molecular inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7: 547-559.